(19)
(11) EP 4 793 364 A3

(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
02.09.2026 Bulletin 2026/36

(43) Date of publication A2:
19.08.2026 Bulletin 2026/34

(21) Application number: 26169307.1

(22) Date of filing: 02.11.2022
(51) International Patent Classification (IPC): 
C12Q 1/6855(2018.01)
(52) Cooperative Patent Classification (CPC):
C12Q 1/6806
 
C-Sets:
  1. C12Q 1/6806, C12Q 2521/501, C12Q 2523/125, C12Q 2525/117, C12Q 2525/191, C12Q 2535/122;
  2. C12Q 1/6806, C12Q 2521/301, C12Q 2521/501, C12Q 2521/539, C12Q 2523/10, C12Q 2523/125, C12Q 2525/117, C12Q 2525/191, C12Q 2535/122;
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 02.11.2021 US 202163274868 P

(62) Application number of the earlier application in accordance with Art. 76 EPC:
22814588.4 / 4426858

(71) Applicant: Guardant Health, Inc.
Palo Alto, CA 94304 (US)

(72) Inventor:
  • KENNEDY, Andrew
    Palo Alto, CA 94304 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) QUALITY CONTROL METHOD


(57) Provided herein are methods for monitoring false negative and/or false positive detection of modified nucleosides in DNA in a sample using a base-pairing conversion procedure. The methods use nucleosides having known nucleoside identity and known modification status in adapters ligated to the DNA. In certain aspects, the disclosure relates to methods for improving the quality control of such methods.







Search report









Search report